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Abstract
Plasmacytoid dendritic cells (pDCs) play a key role in detecting pathogens by producing large amounts of type I interferon
(IFN) by sensing the presence of viral infections through the Toll-Like Receptor (TLR) pathway. TLR9 is a sensor of viral and
bacterial DNA motifs and activates the IRF7 transcription factor which leads to type I IFN secretion by pDCs. However,
during chronic hepatitis B virus (HBV) infection, pDCs display an impaired ability to secrete IFN-a following ex vivo
stimulation with TLR9 ligands. Here we highlight several strategies used by HBV to block IFN-a production through a
specific impairment of the TLR9 signaling. Our results show that HBV particle internalisation could inhibit TLR9- but not
TLR7-mediated secretion of IFN-a by pDCs. We observed that HBV down-regulated TLR9 transcriptional activity in pDCs and
B cells in which TLR9 mRNA and protein levels were reduced. HBV can interfere with TLR9 activity by blocking the MyD88-
IRAK4 axis and Sendai virus targeting IRF7 to block IFN-a production. Neutralising CpG motif sequences were identified
within HBV DNA genome of genotypes A to H which displayed a suppressive effect on TLR9-immune activation. Moreover,
TLR9 mRNA and protein were downregulated in PBMCs from patients with HBV-associated chronic hepatitis and
hepatocellular carcinoma. Thus HBV has developed several escape mechanisms to avoid TLR9 activation in both pDCs and B
lymphocytes, which may in turn contribute to the establishment and/or persistence of chronic infection.
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Introduction
Chronic HBV infection affects more than 400 million people
worldwide and is a major risk factor for developing liver cirrhosis
and hepatocellular carcinoma [1,2]. Infection outcome relies on
the immune system maturity, and approximately 10% of
immunocompetent adults will develop a chronic infection, which
in 10-30% of cases will progress towards liver disease. The
mechanisms involved in viral clearance and persistence still remain
elusive [3]. Several studies report that HBV has developed evasion
strategies that target the adaptive immune responses [3,4], but
many issues of innate immunity during HBV infection remain to
be investigated. Interestingly, the early weeks after infection with
undetectable viremia, followed by high levels of replication, are
not linked to any detectable activation of type I interferons (IFN-
a/b) [5], a key anti-viral response. Plasmacytoid dendritic cells
(pDCs) are important contributers in host defence as they produce
large amounts of type I IFNs, a critical early step for the innate
immune system to control viral replication [6]. The innate
immune response plays an essential role in recognizing microbial
motifs through a panel of pattern recognition receptors (PRR).
The most studied family is the Toll-Like Receptors (TLR), ten
TLRs have been identified in Humans [7]. TLR2 and TLR4
recognize Gram-positive and Gram-negative bacteria cell wall
products respectively. TLR5 recognizes a structural epitope of
bacterial flagellin, whilst TLRs 3, 7 and 8 have been demonstrated
to recognize different forms of viral RNA. TLR9 recognises DNA
sequences from bacteria or viruses in the form of unmethylated
CpG motifs. In humans, TLR9 expression is restricted to pDCs
and B lymphocytes among mononuclear cells [7]. Upon TLR9
stimulation mediated by distinct classes of CpG oligonucleotides
(CpG ODN), pDCs are activated to produce IFN-a/b and various
chemokines, and B lymphocytes are induced to proliferate and
secrete IgM and IL-6 [7]. Despite a narrow expression of TLRs,
i.e. TLR7 and TLR9, pDCs are specialized in virus recognition.
Furthermore, activation of pDCs has a strong impact on
conventional DCs, B, T and NK cells, linking innate and adaptive
immunity through pivotal events [8]. Importantly, functional
impairment of pDCs have been described in several chronic viral
diseases induced by human immunodeficiency virus (HIV),
hepatitis C virus (HCV) and HBV infections [9]. During acute
and chronic HBV infection, reduced numbers of pDCs have been
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26315described in some [10,11,12] but not all [13,14] patient studies. In
this setting, pDCs display a reduced ability to secrete IFN-a in
response to ex vivo TLR9 stimulation (HSV-1 or CpG ODN)
[10,12,13,15]. In HBV-infected patients, massive quantities of
subviral particles (spheres and filaments) containing only envelope
antigens (HBsAg) are produced [3] and uptake of large amounts of
HBsAg by pDC has been shown to impair in vitro TLR9-induced
IFN-a secretion [16]. Moreover, recent reports are highlighting
specific interactions of HIV, HBV, HCV, Epstein Barr virus
(EBV) and Human Papillomavirus (HPV) with regulatory
molecules that impair TLR9 signaling [17].
In this study, we investigated the specific mechanisms leading to
impairment of the TLR9 pathway. Here, we explored the ability
of HBV virions to modulate human pDCs and PBMCs ability to
secrete IFN-a. We also observed for the first time that B cell
expression and function of TLR9 is suppressed by HBV
stimulation.
Results
HBV does not trigger IFN-a secretion by pDCs and PBMCs
despite efficient internalisation
A previous study on the ex vivo analysis of pDCs from highly
viremic HBV carriers suggested a selective uptake of subviral
spherical HBV particles[18]. To assess the ability of pDCs to
internalize both HBV virions and subviral particles, pDCs from
healthy individuals were exposed to HBV at MOI 50 for 1h and
cells were analysed by electron microscopy (Figures 1A). The
specificity of the internalisation was determined by immunogold
labeling using anti-HBsAg antibodies (Figure 1Ai-iii). Anti-HBsAg
staining allowed the identification of HBV Dane particles (42-
45nm, Figure 1Aii-iii) within endosomal structures in pDCs (Ai) as
early as 1h post-exposure. Confocal microscopy was also
performed after 9h of HBV exposure to assess the intensity of
viral and subviral internalisation using anti-HBsAg antibodies
(Figure 1B). Intense HBsAg staining, reflecting mostly subviral
antigen uptake was observed in pDCs, demonstrated by a diffuse
intracytoplasmic or membrane-associated HBsAg staining.
To determine whether HBV could induce a type I IFN response
on immune cells, freshly purified human pDCs and PBMC from
naı ¨ve individuals were exposed to HBV virions for 24h at various
multiplicity of infection (MOI), defined as genome equivalent per
cell (GEq/cell) (Figure 1Ci and ii). Viral antigens HBsAg and
HBeAg were detected within the HBV inoculum by ELISA (data
not shown). We observed that HBV did not induce detectable
levels of IFN-a neither in purified pDCs nor in PBMC as
measured by ELISA (Figure 1Ci and ii). Moreover, immune
complexes generated by incubating HBV virions with anti-HBs
antibodies did not trigger IFN-a secretion in pDCs (data not
shown). As a control, we stimulated both pDCs and PBMC with
the CpG oligonucleotide 2216 (CpG 2216), known to activate a
TLR9-dependent type I IFN response. Following HBV exposure,
moderate levels of IL-10 were induced in PBMC while IL-6
remained below detectable levels (Figure 1Ciii). In summary,
despite an efficient internalisation of HBV virions and subviral
particles within pDCs, no IFN-a secretion but a moderate IL-10
secretion was observed.
HBV impairs CpG-induced IFN-a in pDCs and PBMCs
We next investigated the consequences of viral internalisation
on pDC function. pDCs or total PBMC were stimulated with CpG
2216 in presence of HBV virions at MOI 50 and 100 for 24h
(Figure 2Ai and ii). CpG-induced IFN-a was significantly reduced
in presence of HBV virions (unpaired student t test compared with
NT, p,0,001) and inhibition was dose-dependent in both pDCs
and PBMC. IFN-a secretion was reduced by 35% in pDCs and by
55% in PBMC at MOI 50. More strikingly at MOI 100, HBV
reduced IFN-a secretion in pDCs by 91% and in PBMCs by 75%.
HBV could suppress CpG-induced IFN-a as early as 9h following
stimulation (data not shown). Although HBV is not a cytopathic
virus [4], pDCs viability after 12h of CpG stimulation in the
presence of HBV was assessed using annexin V by flow cytometry
(Supplementary figure S1). No difference was observed in the rate
of annexin V-positive pDCs comparing mock- and HBV-treated
cells. Thus, HBV ability to suppress IFN-a secretion in pDCs is
not caused by induction of cell apoptosis in our experimental
conditions. Since human pDCs express TLR7 and TLR9, we next
tested whether HBV could also impair TLR7-induced IFN-a in
pDCs using loxoribin (TLR7 ligand) or resiquimod/R848 (TLR7/
8 ligand) (supplementary Figure S2A and B) at MOI 50 or 100 for
24h. In contrast to the inhibition observed following TLR9
stimulation, HBV exerted no effect on TLR7-mediated IFN-a
secretion (Supplementary figure S2A and B). We also observed
that HBV virions at MOI 100 were able to inhibit TLR9-
mediated production of IL-6 by CpG 2006 (targeting TLR9 in B
cells [7]), but not TLR7 induction of IL-6 by imiquimod
(Figure 2B). Interestingly, TLR7-mediated IL-6 production was
increased in the presence of HBV virions.
To address a possible involvement of HBsAg in the suppression
of IFN-a secretion [16], purified pDCs and PBMC were
stimulated for 24h with CpG in the presence of increasing
amounts of recombinant HBsAg (adr or ayw3 subtypes (Figure 2Ci
and ii)). CpG-induced IFN-a was neither impaired in pDCs nor in
PBMC exposed up to 1mg of HBsAg, data which were confirmed
using recombinant HBsAg of bacterial origin (data not shown).
HBsAg alone did not induce detectable levels of IFN-a, IL-6 or IL-
10 in pDCs or PBMC (data not shown). Thus, at the concentration
tested, HBsAg was not involved in the HBV-mediated suppression
of IFN-a in pDCs and PBMC.
Since we previously demonstrated that circovirus DNA can
suppress TLR9-mediated activation of pDCs [19], we next
investigated whether the impairment of TLR9-induced IFN-a
may directly involve neutralising CpG sequences within the HBV
DNA itself. For this purpose, 400 complete HBV genome
sequences [20] were analysed for their CpG content and in
particular for CpG-containing hexamers, known to suppress
‘‘classical’’ CpG-mediated immune activation [21]. Our results
suggest that a majority of CpG motifs within HBV genome display
a neutralising structure pattern (CCG, CGG, CGCG) [21],
ranging from 59 to 68% between different HBV genotypes
(Table 1). More importantly, we identified the presence of three
well known neutralising hexamers (GCGGCG, CGCGGG and
GCCGTT [21]) in nearly all HBV genotypes (Table 1). We then
synthetized oligonucleotides derived from HBV DNA containing
these neutralising motifs (A*T*CCTG CGC GGG ACGTC-
C*T*T as ODN HBV; * standing for phosphorothioate link).
ODNHBV1 was found to inhibit CpG 2216-induced IFN-a
secretion in a dose-dependent manner, with 31%, 35% and 41%
of inhibition respectively at 1:1, 2:1 and 3:1 ratio (Figure 2D). In
conclusion, our data suggest that i) HBV virions suppress the
TLR9-mediated secretion of IFN-a and IL-6 in pDCs and B cells
respectively, without any effect on TLR7 signaling and that ii)
HBV DNA sequences negatively affects TLR9-induced IFN-a.
HBV virions down regulate TLR9 mRNA and protein
expression in PBMC
We previously demonstrated that dsDNA oncoviruses such as
HPV16 and EBV down regulate TLR9 transcription [22,23].
HBV Inhibits TLR9 Stimulation of pDCs
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26315Figure 1. HBV does not induce IFN-a and IL-6 in pDCs despite efficient viral and subviral particles internalisation. (A) Internalisation of
HBV virions and subviral particles in pDCs. Freshly isolated pDCs were exposed to HBV at MOI 50 for 1h before cell preparation for immunogold
staining (anti-HBsAg Ab) and electron microscopy. HBV Dane particule of 42-45nm diameter (Aii-iii) in an endosomal-like structure with pDC(Ai).
Magnification and scale bars Ai x7000, 200nm; Aii x150000, 100nm; Aiii x250000, 100nm. Images are representative of two independent blood
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transcripts in PBMC from HBV-infected individuals [24], we
analyzed in vitro the kinetic of down regulation of TLR9 transcripts
in PBMC stimulated with HBV virions. For this purpose, TLR9
mRNA levels were determined by qPCR in cells stimulated with
CpG or the TLR7 ligand imiquimod 6 HBV virions for 7h and
24h. As shown in Figure 3Ai, a 7h treatment with CpG 2216,
CpG2006 or imiquimod down regulated TLR9 mRNA levels
(unpaired Student t test compared with NT; p , 0.001, p , 0.05,
and p , 0.05 respectively). Interestingly, HBV increased TLR9
mRNA levels upon CpG 2216 stimulation. By contrast, at 24h,
HBV strongly down-regulated TLR9 mRNA expression in
untreated PBMC and upon both CpG stimulation of pDCs
(CpG 2216) and B cells (CpG 2006) (Figure 3Aii). As shown in
Figure 3 (B, C), the inhibition of TLR9 mRNA levels correlated
with a reduced TLR9 protein expression in PBMC treated with
HBV for 24h. In accordance with the observation that TLR7
signaling was not affected by HBV (supplementary figure S2A and
B), TLR7 mRNA levels were similar to untreated and CpG2216
treated cells (supplementary Figure S2C), demonstrating that
TLR7 expression is not impaired by HBV virions. Thus HBV
specifically down regulated TLR9 transcription and protein levels
in PBMC.
The TLR9 promoter is down regulated by HBV virions
HBV virions may decrease TLR9 levels by two distinct
mechanisms: HBV can affect the stability of TLR9 transcript or
can directly inhibit the TLR9 transcription as we observed for
HPV16 and EBV [22,23]. To discriminate between these two
possibilities, we have determined whether HBV virions can
influence the activity of the TLR9 promoter. The isolated TLR9
promoter cloned in front of luciferase reporter gene was
introduced by transient transfection in the B cell line RPMI8226,
which expresses high levels of endogenous TLR9, as previously
described [22]. We observed that 24h post-treatment with HBV
(MOI ranging from 30-100), the TLR9 promoter was suppressed
(Figure 4A), as previously shown with HPV E6/E7 protein
expression [22]. Furthermore both mRNA and protein expression
of TLR9 in RPMI8226 B cells were down regulated when treated
for 24h hours with HBV virions (Figure 4B and C), confirming our
findings regarding B cells from PBMC . Thus another strategy
used by HBV to block TLR9 regulated pathways is to down
regulate TLR9 transcription.
HBV virions block IRF7-mediated induction of IFNa4
It has been recently reported that HBsAg inhibited TLR9-
mediated IRF7 expression and nuclear translocation, which are
important for induction of IFN-a gene [16]. In our model, TLR9
induction of IFN-a in pDCs and PBMC was blocked using HBV
virions (Figure 2). TLR9 is known to activate two signaling
pathways dominated by the transcription factors IRF7 and NF-kB.
The IRF7-mediated pathway of signal transduction is responsible
for the transcription of IFN-a and IFN-b. As shown in Figure 5A,
expression of IRF7 in HEK293 cells led to the induction of the
IFNa4 promoter linked to a luciferase reporter gene, which was
further increased by infection with Sendai virus (SV), a ssRNA
virus known to induce the RIG-I-IRF7 signaling pathway [25,26].
Addition of HBV virions to the cells blocked luciferase activity,
arguing for an impairment of the IRF7 pathway (Figure 5A).
Furthermore we observed that SV-enhanced induction of the
IFNa4 promoter by IRF7 was also blocked by HBV virions
(Figure 5B). In order to determine where in the TLR9 pathway
HBV exerts its inhibitory effect, we co-transfected IRF7 with the
IFNa4 promoter 6 MyD88 or IRAK4 constructs in HEK293
cells. We observed that in all cases, HBV down regulated IRF7-
mediated induction of the IFNa4 promoter 6 MyD88 or IRAK4
(Figure 5C). MyD88 or IRAK4 alone did not induce the IFNa4
promoter (Supplementary figure S3). These data indicate that
HBV acts downstream of MyD88 and IRAK4 and upstream of
IRF7 to block IFN-a production.
Chronic HBV carriers (CHB) and hepatocellular carcinoma
patients (HCC) display a reduced TLR9 expression
To corroborate our in vitro data we isolated PBMC from ten
European chronic hepatitis B patients and ten healthy blood
donors (Table 2) and analyzed TLR9 mRNA and protein levels.
CHB patients displayed an overall reduced TLR9 mRNA
expression in comparison to controls (Figure 6i). Interestingly,
TLR9 protein was not detectable in CHB patients, reflecting a
drastic shut down of TLR9 in both pDCs and B lymphocytes, the
latter being identified by CD20 staining (Figure 6ii). In addition,
TLR9 protein levels were also analysed in buffy coats from Asian
individuals, that consisted in 5 CHB, 6 HBV-associated HCC
patients and 5 hospital-based controls (table 2). TLR9 protein was
also drastically reduced in CHB and HCC patients (Figure 6B).
These results show that TLR9 protein levels are drastically
decreased in peripheral pDCs and B cells from patients with HBV-
related liver disease.
Discussion
Increasing evidences are highlighting the role of innate
immunity, and TLR in particular, following HBV infection and
during the course of chronic hepatitis [27,28,29]. This study
provides new insights into the ability of HBV to modulate TLR9
signaling in pDCs and B cells and to inhibit TLR9-mediated IFN-
a and IL-6 secretion. Unlike many viruses which trigger type I
IFNs and have evolved to counteract this activation [30], our data
indicate that HBV does not trigger IFN-a secretion in pDCs
although it can impair its function by a selective TLR9 signaling
blockade. The poor levels of HBsAg glycosylation [31] may
account for the absence of pDC sensing since glycosylation
appears to be a key element for glycoprotein-mediated IFN
induction in pDCs [32]. Our findings show that, in vitro, HBV
virions can inhibit CpG-induced IFN-a in PBMC and purified
pDCs from naı ¨ve individuals, arguing for a direct role of virus-
mediated IFN-a suppression, in correlation with the reduced IFN-
a response following ex vivo stimulation of pDCs from chronic
HBV carriers [10,12,13,15]. We report that HBV can block
TLR9-regulated pathways by down regulating TLR9 transcrip-
tion, reducing TLR9 mRNA and protein levels in total PBMC.
donors, 50 cells examination per donor. (B) HBsAg staining in pDCs following HBV exposure. Freshly isolated pDCs were exposed to mock lysate or
HBV for 9h at MOI 50 prior to fixation and permeabilization for confocal microscopy analysis. HBsAg staining was detected with rabbit polyclonal anti-
HBsAg Ab and Alexa-488 (green) as secondary Ab. Magnification and scale bar, x63; 5 mm. Images are representative of two independent blood
donors. (C) HBV does not induce IFN-a secretion in pDCs and PBMC. Freshly isolated pDCs (Ci) and total PBMC (Cii-iii) were exposed to mock lysate or
HBV at indicated MOI (GEq/cell). Cells were treated with CpG 2216 at 2mM as a positive IFN-a inducer and GpC2116 as a negative control.
Supernatants were collected after 24h and assessed for the presence of IFN-a (Ci-ii), IL-6 and IL-10 (iii) using ELISA. All experiments have been
performed using .3 batches of HBV virus and . 3 blood donors. Shown graphs are representative of 1 of 5 experiments that gave similar results.
doi:10.1371/journal.pone.0026315.g001
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PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e26315Figure 2. TLR9 functionality is impaired in pDCs and PBMCs in the presence of HBV. (A) HBV impairs TLR9-mediated IFN-a induction in
pDCs and PBMC. Purified pDCs (Ai) or total PBMC (Aii) were treated with CpG 2216 (or control GpC 2216) at 2mM 6 HBV at the indicated MOI for 24h.
Supernatants were tested for IFN-a (pg/ml) using ELISA. (B) HBV impairs TLR9-mediated IL-6 in PBMC. Total PBMC were treated with the indicated TLR
ligands 6 HBV (MOI 100) for 24h. Supernatants were tested for IL-6 (pg/ml) using ELISA. (C) HBsAg does not suppress CpG-induced IFN-a. Purified
pDCs (Ci) or total PBMC (Cii) were stimulated with CpG 2216 or control GpC2216 (2mM) 6 increasing concentrations of recombinant HBsAg, adr (clear
grey histogram) or ayw3 subtype (dark grey histogram). Supernatants were collected at 24h and analysed for IFN-a (pg/ml) using ELISA. Experiments
were performed on cells isolated from .3 different blood donors and graphs are representative of 1 of 5 experiments that gave similar results. (D) An
identified HBV-derived ODN sequence inhibits TLR9-mediated IFN-a secretion. PBMC were stimulated with CpG 2216 at 2mM in presence of increasing
concentrations of ODN hbv1 (ratio 1:1, 2:1 and 3:1) for 24h and IFN-a secretion was determined in supernatants using ELISA. Experiments are
representative of .3 independent blood donors.
doi:10.1371/journal.pone.0026315.g002
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expressing TLR9 [22], and since TLR9 levels in PBMC reflect
both pDC and B cell expression, our data suggest for the first time
that HBV can also inhibit TLR9 signaling and transcription in B
cells.
Since circulating DCs do not support HBV replication [18], and
given the ability of pDCs to sense viruses in the absence of
replication, we hypothesised that not only HBV virions, but also
HBV secreted antigens, such as HBsAg, may interfere with CpG-
induced IFN-a secretion. Under our experimental conditions, up
to 1mg of recombinant HBsAg did not affect IFN-a secretion.
However, since HBV replication is associated with the secretion of
tremendous amounts of subviral particles in the blood of HBV-
infected individuals [5], we cannot exclude that higher amounts of
HBsAg or preS1/preS2 antigens may impair TLR9-induced IFN-
a, as recently shown by Xu et al using 25 mg of serum-derived
HBsAg [16]. HBsAg was shown to inhibit TLR9-mediated IRF7
expression and nuclear translocation, which are important for
induction of IFN-a gene expression [16]. Here we showed that
HBV virions block transcription of the IFNa4 promoter induced
either by triggering the MyD88- IRAK4-IRF7 axis or by Sendai
virus infection. We believe that HBV exerts its inhibitory effect on
IFNa4 promoter by directly targeting IRF7. Of note, Epstein-Barr
and Kaposi’s sarcoma viruses have also been shown to down-
regulate IFN-a response in pDCs by blocking IRF7 [30,33].
In addition, we have identified previously characterized
neutralising CpG motifs [21,34] in nearly all HBV genotypes.
Krieg et al [21] first reported the existence of neutralising CpG
motifs in adenovirus DNA that can block CpG-mediated immune
stimulation. Further studies have characterized the suppressive
effects of specific CpG motifs or G and GC-rich ODN on TLR9
activation [35,36]. The identification of neutralising motifs within
HBV DNA suggests that the HBV genome may be involved in
TLR9 silencing in a competitive manner. However, an immuno-
regulatory role for HBV DNA on the TLR9-IFN axis during
chronic HBV infection is presently unknown.
Moreover, in a previous study, we demonstrated that E6 and E7
from human papillomavirus 16 and LMP-1 from EBV have the
ability to downregulate the TLR9 promoter and halter its
functionality [22,23]. Here, we also observed that HBV can
reduce the levels of TLR9 promoter and consequently mRNA
transcripts. We have shown that HPV16 and EBV activate the
NF-kB pathway which in turns acts as a negative regulator of
TLR9 transcription. Many studies have shown that HBx can play
opposite roles regarding the activation of NF-kB [29]. However a
role for HBx in down regulating TLR9 in pDCs is unlikely since
they do not support HBV gene expression. One may argue that a
putative candidate could be the HBV polymerase since it has
recently been shown to inhibit the transcription of the IFN-b gene
in hepatocytes by inhibiting the interaction between IKKe and
DDX3 DEAD box [28]. Overall, distinct mechanisms may be
involved in hepatocytes and pDCs, which, respectively, do not
express TLR9 and are not permissive to HBV infection [18].
By contrast to the inhibition of TLR9-mediated IFN-a
secretion, HBV had no effect on TLR7-induced IFN-a in pDCs.
Similarly, HIV gp120, HCV virions and HPV E6/E7 proteins
have also been shown to suppress TLR9-mediated IFN-a
induction without any effect on TLR7 signaling [22,37,38]. Thus
both TLR pathways might differ at yet unidentified levels and our
results support the hypothesis of a more stringent control of TLR9
Table 1. Percentages of neutralising CpG dinucleotides and CpG-containing hexamer frequencies within HBV genotypes and
subgenotypes.
Genotype
a subgenotype Total CG
b CCG
c CGCG
d CGG
e % CpG-N
f GCCGTT GCGGCG CGCGGG
A A1 100 28 4 27 59 1
A2 103 29 6 28 61 1 1
B B1 101 32 4 28 63 2 1
B2 105 35 5 30 67 2 1
B3 108 37 4 31 67 2 1
B4 109 36 5 30 66 2 1
C C1 106 30 5 33 64 2 2 1
C2 103 33 4 31 66 2 2 1
C3 100 27 4 33 64 1 1
C4 103 31 5 30 64 1 1
D D1 101 31 4 27 61 1 2 1
D2 102 31 4 27 61 1 2 1
D3 101 30 4 27 60 1 2 1
D4 101 33 4 26 62 1 2 1
E9 9 3 3 3 3 0 6 3 1 1
F F1 103 29 4 30 61 1 1
F2 101 31 4 32 66 1 2 1
G9 7 3 3 3 2 6 6 4 1 1
H 101 32 4 32 67 1 1
aanalysis of 400 complete HBV genome sequences was carried out using previously reported HBV sequences [20] and additional data base (H. Norder).
bfrequency of total CpG within HBV genome.
c,d,efrequency of CpG with a neutralising structure pattern [21] within HBV genome.
fpourcentage of neutralising CpG within HBV genome calculated as follow f=(c+d+e)*100/b.
doi:10.1371/journal.pone.0026315.t001
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the host from an overproduction of IFN-a but may also facilitate
virus persistence.
Analysis of PBMC from chronic hepatitis B and HBV-
associated hepatocellular carcinoma patients suggest that TLR9
mRNA levels are downregulated in CHB and that TLR9 protein
is drastically reduced in both CHB and HCC patients. These
findings corroborate our in vitro data in naı ¨ve PBMCs stimulated
with HBV. Such a substantial reduction in TLR9 expression in
chronic HBV carriers has also been observed by others [39]. A
role for HBsAg in the inhibition of TLR9-mediated IRF7
expression and nuclear translocation has been reported [16].
However we have not been able to confirm this hypothesis neither
in vitro, nor with the ex vivo analysis since the number of CHB
patients (10) studied was not sufficient to address potential
correlations between HBsAg quantification and TLR9 mRNA
levels.
Overall, this study demonstrates that HBV virions can
selectively inhibit TLR9 expression in pDCs and B lymphocytes
from PBMC isolated from naı ¨ve and CHB patients. Such
inhibition is associated with a functional loss of TLR9-regulated
pathways. Although the biological significance of HBV-induced
TLR9 impairment remains unclear, recent data suggest that
TLR9 stimulation may induce liver damage (inflammation,
fibrosis, steatosis), involving non-parenchymal liver components
(stellate, Kupffer and sinusoidal endothelial cells) [40]. In this
context, HBV-mediated TLR9 inhibition may reduce liver
inflammation thereby facilitating its persistence within the liver.
Therefore, understanding TLR-HBV interactions holds future
promise not only for the fundamental aspects of HBV persistence
Figure 3. TLR9 mRNA and protein levels are down regulated in the presence of HBV virions in PBMC. (A) HBV down regulates TLR9
mRNA. PBMC were stimulated with the indicated TLR ligands 6 HBV (MOI 100) for 7 hours (Ai) or 24h (Aii). Cells were harvested for RNA extraction
and RT-PCR reaction. The expression level of TLR9 was assessed by qPCR, normalized to the b2-microglobulin expression and expressed relative to
untreated cells. Results are representative of 1 of 5 experiments that gave similar results using .3 different blood donors and 2 independent HBV
stocks. (B) TLR9 protein levels are reduced by HBV virions. PBMC were incubated with HBV or left untreated for 24h. TLR9 expression level was
assessed by immunoblotting and b-actin immunodetection was performed as a loading control. Protein levels were assessed through densitometry
with Fuji Multigauge software. (C) Results are representative of 1 of 2 experiments that gave similar results using two different blood donors and 2
independent HBV stocks.
doi:10.1371/journal.pone.0026315.g003
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strategies for chronic hepatitis B.
Materials and Methods
PBMC and pDCs isolation
Human blood from healthy subjects was obtained from the
French blood agency (Lyon, France). PBMC were separated by
centrifugation on lymphoprep (Abcys). pDCs were either positively
selected with anti-BDCA-4-conjuguated magnetic microbeads or
negatively selected using Plasmacytoid Dendritic Cell Isolation Kit
(Miltenyi Biotec). Purity of sorted pDCs (85 to 95%) was analysed
by staining with anti-BDCA-2 and anti-CD123 monoclonal
antibodies (Miltenyi Biotec) by flow cytometry (FACSCAN).
Viability of stimulated pDCs was assessed using the Annexin-V-
FLUOS Staining Kit (Roche Applied Science). PBMC from
chronic HBV carriers (European samples) and from Asian HBV-
positive patients (CHB and HCC) were obtained with informed
consent from each patient with the procedure approved by the
local Ethics Committee.
In vitro stimulation of PBMC and pDCs
Cells were cultured in RPMI 1640 (Life Technologies)
supplemented with 10% fetal calf serum (Hyclone), 2 mM L-
glutamine (Invitrogen) and antibiotics (Penicillin-streptomycin,
Life Technologies). Freshly isolated PBMC and purified pDCs
were cultured at 5x10
6 cells/ml and 10
5 cells/ml respectively.
Figure 4. TLR9 is down regulated at the promoter, mRNA and
protein level by HBV virions. (A)TLR9 promoter activity is reduced in
RPMI 8226 B cells in the presence of HBV. RPMI 8226 cells were
transfected with the TLR9 promoter, incubated with HBV virions at the
indicated MOI or left untreated for 24h and harvested in total 48h post
transfection. Co-transfection of RPMI 8226 cells with the TLR9 promoter
and HPV16E6E7 or pLXSN constructs was used as positive and negative
controls respectively. Cells were then processed as previously described
for luciferase activity [22]. (B) TLR9 mRNA levels are reduced in RBMI
8226 cells in the presence of HBV virions. Cells were harvested 24h after
treatment for RNA extraction and RT-PCR reaction. The expression level
of TLR9 was assessed by qPCR, normalized to the b2-microglobulin
levels and expressed relative to untreated cells. (C) HBV alters the TLR9
protein levels in RPMI 8226 cells. Cells were treated as indicated and
protein extracts were prepared 24h later. TLR9 protein level was
assessed by immunoblotting. b-tubulin served as a loading control.
Graphs shown are representative of 1 of 5 experiments that gave similar
results using 3 batches of HBV virus.
doi:10.1371/journal.pone.0026315.g004
Figure 5. The IRF7-mediated induction of the IFNa4 promoter
is suppressed by HBV. (A) Co-transfection of the IFNa4 promoter
(500 ng) with the IRF7 expression plasmid or the control vector (750 ng)
was performed in HEK293. After 24h cells were incubated with HBV
(MOI 100) and/or SV and luciferase activity was measured post total
48h. (B) HEK293 cells were co-transfected with the expression vectors
indicated (750 ng) with the IFNa4 promoter (500 ng). After 24h cells
were treated as described above and luciferase activity was measured
post 48h. Values represent the mean of three independent experiments
performed in triplicate.
doi:10.1371/journal.pone.0026315.g005
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CpG2216, the control GpC2006 or GpC2116 at 2mM (Invivo-
gen,). TLR7 stimulation was performed using 3 distinct ligands,
loxorubine at 1mM, resiquimod at 1mM (TLR7/8) and imiquimod
at 4mM (Invivogen). Supernatants were collected after stimulation
at indicated time points and cytokines (IFN-a; IL-6 and IL-10)
were determined using specific ELISAs with respective sensitivity
of 8; 1,5; 1,6 and 3,1pg/ml (Abcys).
Hepatitis B virus, recombinant antigens and HBV-derived
ODN
HBV inoculum was a 100-fold concentrated culture supernatant
from HepG2.2.15 cells or HBV infected-HepaRG cells [41,42].
Briefly, supernatants were clarified, layered onto a sucrose cushion
(10 and 20% in 20 mM Tris, pH 8) and centrifuged at 4uC for 16h at
25,000 rpm using a SW41 rotor (Beckman). HBV inoculum was also
obtained following concentration using Centricon Plus-70 (Biomax
100, Millipore Corp). Similar procedure was applied to HepG2 or
HepaRG cells supernatants to generate the mock lysate. HBV stock
titre (genome equivalent/ml, GEq/ml) was assessed using real time
PCR [43]. Recombinant HBsAg, adr (0,69mg/ml) and ayw3
(0,88mg/ml)subtypes,wereprovidedbyBioMe ´rieux[44]. Endotoxin
levelsinrecombinantHBsAgwerelessthan0,01EU/mlwithinHBV
stocks (Limulus amoebocyte lysate assay, BioWhittacker). HBV-
derived ODN (table 2) were synthetised by Eurogentec, resuspended
in endotoxin-free water and used at 2mM. Sendai virus (SV, Cantell
strain; Charles River, SPAFAS) was added directly to the cells to give a
final concentration of 80 hemagglutinin (HA) units/ml.
Electron and confocal microscopy
pDCs were prepared for electron microscopy as previously
described [45] and immunogold labelling was performed using a
rabbit anti-HBsAg antibody (MA Petit, INSERM U871). Obser-
vations were performed on a JEOL JEM 1400 transmission
electron microscope (Jeol Ltd) equipped with Gatan Orius camera
and Analysis Soft Imaging System (Eloı ¨se SARL). For confocal
microscopy, purified pDCs were fixed with 4% paraformaldehyde
in PBS for 20 min at room temperature. Cells were permeabilized
in 0,5% saponin with 5% BSA for 30 min at room temperature.
Cells were washed in 0,1% saponin/PBS and incubated with
primary rabbit anti-HBsAg antibody for 2h at room temperature
followed by incubation with secondary goat anti-rabbit Alexa fluor
488 (Invitrogen Life Technologies) performed for 1h at room
temperature. After mounting with Cytomation medium (DAKO),
cells were examined using a Pascal 510 ZEISS LSM microscope
and imaged using Zeiss LSM Image Browser.
Table 2. Characteristics of patients with chronic hepatitis B (CHB), HBV-related hepatocellular carcinoma (HCC) and healthy
controls from European and Asian origins.
European patients (n) Age (year) M/SD gender HBeAg HBsAg (IU/ml) Viremia (IU/ml)
Controls (10 ; 1 to 10) 32,3 /12,5 5M - 5F NEG NEG NEG
CHB patients (10)
Patient 11 36 M NEG 861,2 undetectable
Patient 12 60 F NEG 96,8 undetectable
Patient 13 59 F NEG 38,6 undetectable
Patient 14 43 M NEG 430,5 511
Patient 15 28 F NEG 5817,5 2,4.10
6
Patient 16 32 F POS .25000 48.10
6
Patient 17 51 F NEG 5328,8 undetectable
Patient 18 50 M NEG 104,9 undetectable
Patient 19 57 F NEG 1416 2550
Patient 20 66 M NT NT undetectable
Asian patients (n) Age (year) gender HBeAg HBsAg Viremia (DNA copie/ml)
Controls (6 ; A to F) 54,8 /8,4 6M NEG NEG NEG
HCC patients (6)
Patient G 44 M NT POS 5,6.10
6
Patient H 47 M NT POS 25.10
6
Patient I 53 M NT POS 3,7.10
6
Patient J 42 M NT POS 2,7.10
6
Patient K 61 F NT POS 79.10
6
Patient L 59 M NT POS 22.10
6
CHB patients (5)
Patient M 58 F NT POS 0,76.10
6
Patient N 56 F NT POS 1,8.10
6
Patient O 50 M NT POS 4,8.10
6
Patient P 57 F NT POS 5,5.10
6
Patient Q 58 F NT POS 23.10
6
CHB, chronic hepatitis B ; HCC, hepatocellular carcinoma; NT not tested; Age M, median; SD standard deviation; All patients are negative for hepatitis C infection.
doi:10.1371/journal.pone.0026315.t002
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Total cellular RNA was extracted from PBMC using the RNA
extraction kit (Qiagen) or the protein/RNA extraction kit
(Macherey-Nagel). cDNA synthesis was performed with 1 mgo f
total RNA with the First Strand cDNA Synthesis kit (MBI
Fermentas). qPCR was performed using the Mx3000P real-time
PCR system (Strategene) with Mesa green qPCR MasterMix plus
(Eurogentec) and TLR9 and b2mglobulin specific primers for
relative quantification [22,23].
The expression level of human TLR7 was determined by semi-
qPCR using TLR7 and GAPDH primers. Each reaction was run
in duplicate.
Constructs
The Expression vector for human IRF7 plasmid construct and
the human IFNa4 promoter cloned in front of firefly luciferase
(IFNa4-PGL3) were kindly provided by Kate Fitzgerald (UMass
Medical School, MA, USA). The -3227TLR9-pGL3 reporter
plasmid, the retroviral vector HPV16E6E7 and the control
pLXSN have been previously described [22]. The expression
vector for MyD88 and for IRAK4 have been previously described.
Transient transfection and luciferase assay
RPMI 8226 and HEK293 cells have been transiently transfect-
ed in triplicate using Fugene 6 (Roche Applied Science) and Gene
Juice (Novagen) respectively and luciferase assay was performed as
previously described [22].
Immuno-blot analysis
Total protein extracts were obtained with the protein/RNA kit
(Macherey-Nagel) following manufacturer’s instructions. Twenty
mg of protein extracts were quantified with the protein quantifi-
Figure 6. TLR9 mRNA and protein expression is impaired in CHB and HCC patients. (A) CHB patients present a reduced TLR9 mRNA and
protein level. PBMC were processed for RNA extraction (Ai) and protein extraction (Aii). TLR9 mRNA expression level was assessed in qPCR, normalized
to b2-microglobulin and expressed relative to an healthy donor (sample number 3). TLR9 and CD20 protein levels were determined by
immunoblotting and b-tubulin served as a loading control. (B) TLR9 protein expression is inhibited in CHB and HCC patients. Buffy coats were
processed for protein extraction. TLR9 and b-tubulin (the loading control) were detected by immunoblotting.
doi:10.1371/journal.pone.0026315.g006
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ting were TLR9 (Cell Signaling), b-tubulin (Sigma), b-Actin (MP-
biomedicals) and CD20 (BD Pharmingen). Western blots were
developed using the intelligent dark box (Fuji film).
Statistics
GraphPad (version 5) was used to calculate unpaired and paired
p values: ***, extremely significant, p , 0.001; **, very significant,
p = 0.001-0.01; *, significant, p = 0.01-0.05; and ns, p . 0.05.
Supporting Information
Figure S1 Suppressed IFN-a production is not caused by
increased pDC apoptosis. pDCs were treated with CpG 2216
6 HBV at MOI 100 or 50 for 12h. Cells were stained with
Annexin V
FITC by flow cytometry and percentages in gate R1
represent early apoptotic pDCs.
(TIF)
Figure S2 HBV does not impair TLR7-induced IFN-a
and does not modulate TLR7 transcripts. pDCs were
stimulated with TLR7 ligand loxoribine (Lox) at 1mM (A) or
TLR7/8 ligand resiquimod (Res) at 1mM (B) 6HBV at MOI 50 or
100. Supernatants were collected after 24h and tested for IFN-a
(pg/ml) by ELISA. Experiments were performed on cells isolated
from 3 different blood donors. (C) HBV does not modulate TLR7
mRNA in pDCs. PBMC were stimulated with CpG 2216 or
GpC2216 in presence of mock lysate or HBV at MOI 50. After
20h, cells were harvested for RNA extraction, and RT-PCR was
performed for TLR7 and GAPDH expression. Densitometry levels
were determined using the Bio-Rad phosphoimaging software.
Results are representative of 3 different blood donors and 2
independent HBV stocks.
(TIF)
Figure S3 Over-expression of IRF7 in HEK293 cells
leads to IFNa4 promoter activation. Cells were co-
transfected with IFNa4-pGL3 reporter plasmid together with the
indicated plasmids. After 48h luciferase assay was assessed as
described previously [20] .
(TIF)
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